trending Market Intelligence /marketintelligence/en/news-insights/trending/5cL4qJc3ZNhA2BMnzwcz0w2 content esgSubNav
In This List

Cara Therapeutics starts $80M common stock offering

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Cara Therapeutics starts $80M common stock offering

Cara Therapeutics Inc. started an underwritten public offering of $80 million of its common shares.

The company expects to grant the underwriters an option to buy up to $12 million of additional shares.

Cara plans to use the proceeds to fund its clinical and research development activities, including the completion of the phase 3 program for I.V. CR845 in uremic pruritus, two phase 3 trials of I.V. CR845 in acute pain and a phase 2b trial of oral CR845 in osteoarthritis pain, as well as for working capital and general corporate purposes.

Piper Jaffray & Co. and Stifel are acting as joint book-running managers for the proposed offering.